Research from NCMM PhD student could help fight E.coli

With increasing antibiotic resistance, we need new treatments for disease-causing E.coli. Julia Weikum, a former PhD student in the Morth group, will shortly defend her thesis: “Bacterial protein systems at the membrane interface: Structural and biophysical studies of the E.coli adhesion receptor intimin and the magnesium transporter MgtA"

Photo of Juila Weikum

Julia Weikum. Photo: Private/UiO

Escherichia coli , more commonly known as E. coli, is an important intestinal bacterium in humans and other animals. It breaks down sugar, produces vitamin K, which is needed for blood to coagulate. Our intestines contain so much E.coli that the dead bacteria make up a third of our stool. 

However, some strains of this useful bacterium can cause life-threatening illness and outbreaks regularly occur around the world. For example, in 2011 a deadly outbreak of E.coli in Germany killed 50 people. Outbreaks are more common in developing countries with poorly developed healthcare systems, but outbreaks in developed regions can still have serious consequences. There is now a growing threat posed by antibiotic resistance, meaning that E.coli infections that might have once been treatable with antibiotics are now becoming impossible to treat. New therapies and approaches are therefore needed. Julia Weikum, a PhD student in the Morth Group at NCMM is one of those researchers investigating alternative treatment strategies.

She will defend her PhD on 20 November at the Department of Pharmacy, UiO. Details of the defence via this link.  

Read more: Frykta tarmbakterie gjev frå seg hemmelegheiter (Norwegian only) on 


Published Nov. 6, 2020 3:44 PM - Last modified Nov. 6, 2020 3:46 PM